-

Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date

Conference call to be on Tuesday, July 2, 2024, at 5 p.m. EDT

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report third quarter fiscal 2024 financial results after the market close on Tuesday, July 2, 2024.

Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on the investor relations page of the Simulations Plus website at www.simulations-plus.com/investorscorporate-profile/corporate-profile/ where it will also be available for replay approximately one hour following the call.

About Simulations Plus

With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the Biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.

Contacts

Simulations Plus Investor Relations
Renee Bouche
661-723-7723
renee.bouche@simulations-plus.com

Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com

Industry:

Simulations Plus, Inc.

NASDAQ:SLP
Release Summary
Simulations Plus will report 3rd quarter FY24 earnings and host a conference call to discuss the financial results on July 2, 2024, at 5pm EDT.
Release Versions
English

Contacts

Simulations Plus Investor Relations
Renee Bouche
661-723-7723
renee.bouche@simulations-plus.com

Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com

Social Media Profiles
Simulations Plus on LinkedIn
Simulations Plus on X
More News From Simulations Plus, Inc.

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded partnership with a global large pharmaceutical company to apply Turin, its AI-enabled scientific engine for quantitative systems pharmacology (QSP), within an active therapeutic development program. The collaboration will evaluate how AI-enabled...

Simulations Plus Announces Completion of Acquisition by Altaris

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the completion of its acquisition by affiliates of Altaris, LLC ("Altaris"), an investment firm focused exclusively on the healthcare industry.The transaction was originally announced on June 16, 2026. At the effective time of the merger each Simulations...

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration’s (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technology...
Back to Newsroom